Halozyme Therapeutics | HALO - Trade Debtors

Stock Price
68.82
Daily Change
-0.40 -0.58%
Monthly
-5.51%
Yearly
16.35%
Q1 Forecast
68.78

Halozyme Therapeutics reported $441.27M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Agios Pharmaceuticals USD 10.58M 5.55M Dec/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Amarin USD 127.31M 8.18M Sep/2025
Amgen USD 9.57B 1.08B Dec/2025
Baxter International USD 2.01B 231M Dec/2025
Cara Therapeutics USD 2.24M 2.26M Mar/2025
Cytokinetics USD 1.81M 6.6M Sep/2025
DBV Technologies USD 15.97M 279K Sep/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Esperion Therapeutics USD 60.36M 5.75M Jun/2024
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
MannKind USD 38.37M 20.98M Dec/2025
Nektar Therapeutics USD 0 2.9M Sep/2024
Pfizer USD 18.12B 2.02B Sep/2025
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
United Therapeutics USD 350.2M 52.5M Dec/2025
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024